Abstract: The present invention relates to DNA formulations suitable for ballistic delivery into the skin of the human body. In particular the present invention provides DNA formulations suitable for ballistic administration of DNA vaccines into the skin. The present invention provides a novel DNA pharmaceutical agent dosage form, having a dense core element which is coated with an amorphous solid reservoir medium containing the DNA pharmaceutical agent.

Abstract: The present invention relates to novel compositions comprising DNA attached to an immunostimulatory oligonucleotide (CpG) via a locked nucleic acid oligonucleotide of a defined sequence. In particular the present invention provides compositions comprising a plasmid containing a gene encoding a protein of interest, wherein said plasmid may be introduced to a tissue or cell and the gene expressed, complexed to the LNA-CpG. Also provided is a method of co-synthesis of CpG and LNA to form compositions for use as adjuvants with DNA plasmid vaccines.

Abstract: The present invention relates to DNA formulations suitable for ballistic delivery into the skin of the human body. In particular the present invention provides DNA formulations suitable for ballistic administration of DNA vaccines into the skin. The present invention provides a novel DNA pharmaceutical agent dosage form, having a dense core element which is coated with an amorphous solid reservoir medium containing the DNA pharmaceutical agent.

Abstract: The present invention relates to efficient devices for administration of DNA based pharmaceutical agents into mammalian skin. In a particularly preferred aspect of the present invention there is provided devices for administration of DNA vaccines into the skin of the mammal, and preferably into human skin. The present invention provides a microneedle DNA pharmaceutical agent delivery device having at least one skin-piercing element which compromises a support member coated with a solid reservoir medium containing, in solid solution or suspension within it, the DNA pharmaceutical agent, and a stabilising agent that inhibits the degradative effects of free radicals. Preferably the solid pharmaceutical reservoir medium coated onto such devices is a polyol, preferably being a polyol in an amorphous state (such as a glass).

Abstract: The present invention relates to compositions comprising DNA attached to one or more functional moities via a locked nucleic acid oligonucleotide.